Literature DB >> 19372181

The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Mucositis: from febrile neutropenia to febrile mucositis.

Nicole M A Blijlevens1, Richard M Logan, Mihai G Netea.   

Abstract

The treatment of patients with cancer is often accompanied by life-threatening complications caused by chemotherapy and radiotherapy. They are known to result from neutropenia, but damage to the mucosal barrier as well as the humoral and cellular immune defences play a significant role in various infectious complications and aggravate diverse inflammatory processes. The article describes the journey from febrile neutropenia to febrile mucositis in patients treated with immunocompromising therapy.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19372181     DOI： 10.1093/jac/dkp081

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  14 in total

Review 1.  Host-Microbiome Cross-talk in Oral Mucositis.

Authors:  R M Vasconcelos; N Sanfilippo; B J Paster; A R Kerr; Y Li; L Ramalho; E L Queiroz; B Smith; S T Sonis; P M Corby
Journal:  J Dent Res       Date:  2016-04-06       Impact factor: 6.116

2.  Topical curcumin can inhibit deleterious effects of upper respiratory tract bacteria on human oropharyngeal cells in vitro: potential role for patients with cancer therapy induced mucositis?

Authors:  Sonja Lüer; Rolf Troller; Marion Jetter; Violeta Spaniol; Christoph Aebi
Journal:  Support Care Cancer       Date:  2010-05-14       Impact factor: 3.603

3.  Impact of oral hygiene on febrile neutropenia during breast cancer chemotherapy.

Authors:  Kanako Suzuki; Shinsuke Sasada; Hiromi Nishi; Yuri Kimura; Tomoaki Shintani; Akiko Emi; Norio Masumoto; Takayuki Kadoya; Hiroyuki Kawaguchi; Morihito Okada
Journal:  Breast Cancer       Date:  2022-10-21       Impact factor: 3.307

4.  Local and systemic pathogenesis and consequences of regimen-induced inflammatory responses in patients with head and neck cancer receiving chemoradiation.

Authors:  Elvio G Russi; Judith E Raber-Durlacher; Stephen T Sonis
Journal:  Mediators Inflamm       Date:  2014-03-16       Impact factor: 4.711

Review 5.  Biomarkers and non-invasive tests for gastrointestinal mucositis.

Authors:  N S S Kuiken; E H H M Rings; N M A Blijlevens; Wim J E Tissing
Journal:  Support Care Cancer       Date:  2017-05-24       Impact factor: 3.603

6.  Reduced microbial diversity in adult survivors of childhood acute lymphoblastic leukemia and microbial associations with increased immune activation.

Authors:  Ling Ling Chua; Reena Rajasuriar; Mohamad Shafiq Azanan; Noor Kamila Abdullah; Mei San Tang; Soo Ching Lee; Yin Ling Woo; Yvonne Ai Lian Lim; Hany Ariffin; P'ng Loke
Journal:  Microbiome       Date:  2017-03-20       Impact factor: 14.650

Review 7.  The impact of the oral cavity in febrile neutropenia and infectious complications in patients treated with myelosuppressive chemotherapy.

Authors:  Judith A E M Zecha; Judith E Raber-Durlacher; Alexa M G A Laheij; Anneke M Westermann; Joel B Epstein; Jan de Lange; Ludi E Smeele
Journal:  Support Care Cancer       Date:  2019-06-20       Impact factor: 3.603

8.  Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice.

Authors:  Bojidar M Kojouharov; Craig M Brackett; Jean M Veith; Christopher P Johnson; Ilya I Gitlin; Ilia A Toshkov; Anatoli S Gleiberman; Andrei V Gudkov; Lyudmila G Burdelya
Journal:  Oncotarget       Date:  2014-02-15

9.  IL-33 targeting attenuates intestinal mucositis and enhances effective tumor chemotherapy in mice.

Authors:  R Guabiraba; A G Besnard; G B Menezes; T Secher; M S Jabir; S S Amaral; H Braun; R C P Lima-Junior; R A Ribeiro; F Q Cunha; M M Teixeira; R Beyaert; G J Graham; F Y Liew
Journal:  Mucosal Immunol       Date:  2014-01-15       Impact factor: 7.313

Review 10.  Host impairments in patients with neoplastic diseases.

Authors:  J Peter Donnelly; Nicole M A Blijlevens; Walter J F M van der Velden
Journal:  Cancer Treat Res       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.